CollPlant Biotechnologies specializes in regenerative and aesthetic medicine, offering products for tissue regeneration and organ production. Their technology relies on plant-based production of collagen type I (rhCollagen).
CollPlant Biotechnologies New (CLGN) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, CollPlant Biotechnologies New's actual EPS was -$0.34, missing the estimate of -$0.28 per share, resulting in a -21.21% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
